Adar Poonawalla set to buy London’s most expensive house worth ₹1446 crore
Serum Institute of India (SII) CEO Adar Poonawalla is all set to buy the most expensive house of London. According to media reports, the house in London bagged the title of being the most expensive house in 2023 and is worth ₹1446 crore.
Adar Poonawalla is the CEO of Serum Institute of India (SII), which makes the Covishield vaccine.
A CNBC report confirmed the deal wherein Adar Poonawalla will buy the most expensive house in London. The 42-year old Indian billionaire will pay ₹1446 crore for the nearly a century old Aberconway House near Hyde Park.
According to the CNBC report, expensive Londn House will be acquired by Serum Life Sciences, a UK subsidiary of the Adar Poonawalla family’s Serum Institute of India (SII). This deal will make Aberconway House the second-most expensive home ever sold in London.
The priciest residential transaction in London occurred in January 2020 when 2-8a Rutland Gate was sold for a record-breaking £210 million. Originally, attributed to the estate of the former Saudi Arabian crown prince Sultan bin Abdulaziz, recent revelations disclosed that the actual buyer was Hui Ka Yan, the founder and chair of Evergrande.
Serum Institute of India Ltd. became the world’s biggest vaccine maker by producing low-cost inoculations for developing nations that other companies wouldn’t.
A Bloomberg report says, now Adar Poonawalla’s Serum Institute is looking to tap the rich world’s need for those shots as well.
The Bloomberg report says, over the next three years, Pune-based Serum plans to start production of yellow fever and dengue shots for European and American travelers to countries where those diseases are endemic, Chief Executive Officer Adar Poonawalla said in an interview.
That would add higher-margin products to the company’s growing suite of immunizations, which include a sub-$4 malaria shot that was approved by the World Health Organization this week.
Serum, a family-owned business that branched out from racehorse-breeding, has thrived by targeting neglected diseases that plague the world’s poorest places. With its Covid-19 shots and plans for a so-called childhood TDAP vaccine that targets a constellation of ailments like whooping cough, the company is looking to expand in more competitive, and potentially more profitable, markets.
Milestone Alert!Livemint tops charts as the fastest growing news website in the world 🌏 Click here to know more.
Download The Mint News App to get Daily Market Updates.
Published: 12 Dec 2023, 02:37 PM IST
